




OPEN-LABEL TRUNCAL STUDY

POLYMERIC EMULSION TECHNOLOGY

HELPS IMPROVE SKIN BARRIER FUNCTION^{1, 2}

Unique Formulation



EXPLORE THE UNIQUE MECHANISM
OF DELIVERY FOR ARAZLO LOTION

Watch and learn how patented polymeric emulsion technology distributes tazarotene evenly to reduce irritation, facilitates rapid absorption of hydrating excipients that strengthen barrier function, to deliver the clearance you expect and the tolerability you want¹⁻⁵

Even Distribution

FORMULATED TO DISTRIBUTE EVENLY AND REDUCE IRRITATION¹

The vehicle in ARAZLO Lotion features a honeycomb mesh that spreads tazarotene evenly on the skin.¹

The clinical significance of the formulation has not been established.

Magnification

OIL DROPLETS



When applied, the honeycomb mesh distributes the oil droplets evenly on the skin¹


Barrier Function

IMPROVES BARRIER FUNCTION²



In addition to the tazarotene-containing oil droplets, the honeycomb mesh evenly distributes moisturizing components that form a barrier to help keep the skin from losing moisture.¹


- 8 hours after vehicle application the skin barrier was 51% more effective at retaining water than at baseline²



IMPROVES WATER RETENTION²



- 15 and 30 minutes after vehicle application, there was 107% more water in the skin than at time 0 as measured by corneometry²
- 24 hours after application, the water content in the skin was 38% greater than at baseline²



Patient Friendly

DESIGNED TO PROMOTE PATIENT ACCEPTANCE¹




Excipients with hydrating properties include¹:

- Diethyl sebacate
- Light mineral oil
- Sorbitol solution, 70%

In a survey, 100% of patients (N=15) strongly agreed or agreed that the ARAZLO Lotion vehicle had these qualities^{1,2}:

- Absorbed quickly
- Did not feel greasy
- Had a lightweight after-feel



Indication

ARAZLO® (tazarotene) Lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.

Important Safety Information

ARAZLO Lotion is for topical use only. Not for oral, ophthalmic, or intravaginal use.

Contraindication

ARAZLO Lotion is contraindicated in pregnancy due to the potential harm to the fetus.

Warnings and Precautions

Embryofetal Risk Females of childbearing potential should be warned of the potential risk and should use adequate birth-control measures when ARAZLO Lotion is used. A negative result for pregnancy should be obtained within 2 weeks prior to ARAZLO Lotion therapy, and therapy begun during a menstrual period. If the patient becomes pregnant while using ARAZLO Lotion, treatment should be discontinued.

Skin Irritation Patients using ARAZLO Lotion may experience application site pain, dryness, exfoliation, erythema, and pruritus. Depending upon severity, adjust or interrupt dosing as needed, increasing or resuming treatment as tolerated. Avoid application of ARAZLO Lotion to eczematous or sunburned skin.

Photosensitivity and Risk for Sunburn Minimize unprotected exposure to ultraviolet light, including sunlight, sunlamps and tanning beds, during the use of ARAZLO Lotion. Warn patients with high levels of sun exposure and those with inherent sensitivity to sun to exercise caution. Instruct patients to use sunscreen products and protective clothing over treated areas when sun exposure cannot be avoided.

ARAZLO Lotion should be administered with caution if the patient is taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

Weather extremes, such as wind or cold, may be more irritating to patients using ARAZLO Lotion.

Adverse Reactions The most common adverse reactions (in ≥1% of patients and greater than vehicle) were: application site pain, dryness, exfoliation, erythema, and pruritus.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Please [click here](#) for full Prescribing Information.

REFERENCES: 1. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. *J Dermatol Treat.* 2019.1-8. 2. Data on file. 3. ARAZLO Lotion [prescribing information]. Bridgewater, NJ. Bausch Health US, LLC. 4. Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. *J Drugs Dermatol.* 2019;18(6):542-548. 5. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. <https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm>. Accessed May 19, 2021.

[CONTACT US](#) | [PRIVACY POLICY](#) | [COOKIES POLICY](#) | [LEGAL NOTICE](#) | [SITE MAP](#)



Follow us
on LinkedIn

© 2022 Ortho Dermatologics' affiliated entities. ARZ.0165.USA.20V3.0

CALIFORNIA RESIDENTS: [DO NOT SELL MY PERSONAL INFORMATION](#)